Search Technologies

Scientists at the National Cancer Institute (NCI) developed a novel stealth lipid-based nanoparticle formulation comprising phospholipid, DC8,9PC and a polyethylene glycol-ated (PEGylated) lipid – such as DSPE-PEG2000 – that efficiently package a high amounts of hydrophobic photodynamic drug (PDT) – such as HPPH – in stable vesicles. This HPPH-loaded liposome system demonstrates higher serum stability and ambient temperature stability upon storage. It exhibits increased tumor accumulation and improved animal survival in mice tumor models compared to the formulation in current clinical trials. The NCI seeks co-development partners and/or corporate licensees for the application of the technology as an anti-cancer therapeutic.

Scientists at the National Institute on Drug Abuse (NIDA) have developed novel dopamine D3 receptor (D3R) agonists with high affinity and selectivity. Two lead compounds, 53 and eutomer 53a, have demonstrated significantly higher D3R binding selectivity than reference compounds. Moreover, 53 and 53a showed metabolic stability in liver microsomes, which is favorable for the future use of these compounds as therapeutic agents for diseases related to dopamine system dysregulation such as Parkinson’s Disease and Restless Legs Syndrome. Researchers at NIDA seek licensing and/or co-development research collaborations for the use of these D3R agonists as molecular tools for the study of D3R physiology and as potential therapeutics to treat neurological and neuropsychiatric disorders.

The National Cancer Institute (NCI) seeks licensees for a fluoro-azacitidine analog that is efficacious in murine models of colon cancer, leukemia, and Hodgkin lymphoma.

Multi-potential hematopoietic progenitor cells (HPC) can differentiate into any class of blood cells, and are highly useful in regenerative medicine, immunology, and cancer immunotherapy. Current methods to generate HPCs are limited either due to the use of animal products, or the high cost and low efficiency of animal product free systems. Researchers at the National Cancer Institute (NCI) have developed a protocol to prepare HPCs from human induced pluripotent stem cells (hiPSC), using human mesenchymal stem cells (hMSC) in a three-dimensional (3D) co-culture condition. Thus, they are able to generate HPCs in a fully human, autologous system, which can be used to further generate immune cells for therapy. This protocol is adaptable to mass production by bioreactors. NCI seeks licensees for these methods of generating HPCs in a 3D co-culture with hMSCs to be used in a variety of applications such as treatment of blood disorders, regenerative medicine, and antibody production.

The Eunice Kennedy Shriver National Institute of Child Health and Human Development seeks research co-development partners and/or licensees further to develop and commercialize its novel cells and populations thereof for the treatment of oncological, bacterial, fungal and other conditions.

Regulatory B-cells (Breg) play an important role in reducing autoimmunity and reduced levels of these cells are implicated in etiology of several auto-inflammatory diseases. Despite their impact in many diseases, their physiological inducers are unknown.  The National Eye Institute seeks parties interested in licensing or collaborative research to co-develop a process for the production of regulatory B-Cells for use in auto-immune indications.

Researchers at the National Institutes on Aging (NIA) seek research co-development or licensees for novel compounds and pharmaceutical formulations to treat autoimmune disorder and inflammation. Other potential indications for these compounds include pain, itching, and/or skin disorders.

Researchers at the National Cancer Institute (NCI) developed several high-affinity monoclonal antibodies to treat Fibroblast Growth Factor Receptor 4 (FGFR4)-related diseases including rhabdomyosarcoma and cancers of the liver, lung, pancreas, ovary and prostate. These antibodies have been used to generate antibody-drug conjugates (ADCs) and chimeric antigen receptors (CARs), which are capable of specifically targeting and killing diseased cells. NCI seeks co-development opportunities or licensees for this technology.

Researchers at the National Cancer Institute (NCI) seek research collaborations or licensees for a monoclonal antibody targeting TEM8 and related conjugates. The antibody and antibody drug conjugates (ADC) containing the antibody of the current invention were tested in vivo and have potential for use in cancer immunotherapy.